Posted by Michael Wonder on 22 Mar 2023
Sandoz receives US FDA approval for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation
21 March 2023 - Biosimilar Hyrimoz (adalimumab-adaz) high-concentration formulation approved for seven indications of reference medicine Humira.
Sandoz today announced that the US FDA approved a citrate-free high concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection.
